Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Pharmacyclics, Inc. today reported financial results for its fiscal year and fourth quarter which ended June 30, 2010.

14 Sep 2010

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 7th International Melanoma Research Congress in Sydney, Australia, on November 4, 2010 at 4:30 p.m., as part of the 4th Interdisciplinary Melanoma & Skin Cancer Centres Meeting,

13 Sep 2010

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

Incyte Corporation announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) for the design of a pivotal Phase III trial for its JAK1 and JAK2 inhibitor, INCB18424 in patients with polycythemia vera (PV), a blood cancer that belongs to a group of diseases known as myeloproliferative neoplasms (MPNs).

13 Sep 2010

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced the initiation of the pivotal Phase 2 clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL).

13 Sep 2010

LabCorp acquires Genzyme Genetics for $925 million

Laboratory Corporation of America Holdings, today announced that it has entered into a definitive agreement under which LabCorp will acquire Genzyme Genetics, a business unit of Genzyme Corp., in an all cash transaction valued at $925 million. Net of expected income tax benefits, less acquisition related expenses, the acquisition has a net cash cost to LabCorp of approximately $795 million.

13 Sep 2010

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a pivotal Phase 3 trial for the Company's sapacitabine oral capsules as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy.

13 Sep 2010

LabCorp signs five-year agreement with Sysmex America to provide hematology systems

Sysmex America, Inc., a leading medical diagnostic instrument manufacturer and information systems developer, today announced that Laboratory Corporation of America Holdings (LabCorp) has signed a five-year agreement for Sysmex America, Inc. to provide fully automated hematology systems for LabCorp's primary testing laboratories.

From Sysmex America, Inc. 13 Sep 2010

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Among Asian-Americans living in California, Laotian/Hmong-Americans have the lowest survival rates for the most common type of liver cancer, a new study by researchers with the UC Davis School of Medicine has found.

10 Sep 2010

Researchers find risk prediction model for VTE in cancer patients

For cancer patients, who have an increased risk of developing venous thromboembolism (VTE) due to a hyperactive blood coagulation system, there is now an enhanced risk model to predict their chance of developing blood clots, according to a recent study published today in Blood, the journal of the American Society of Hematology.

10 Sep 2010

IMF and CHPF join to promote awareness of myeloma in China

The International Myeloma Foundation (IMF), the oldest and largest foundation dedicated to improving the life and care of myeloma patients, today announced plans to sign a cooperative agreement with the Chinese Health Promotion Foundation (CHPF), an agency that operates under the Chinese Ministry of Health, to promote awareness of myeloma in China and to encourage measures to prevent and combat the disease.

9 Sep 2010

$GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL$

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

GlaxoSmithKline and Genmab A/S announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin's lymphoma (B-NHL) who did not respond to or progressed during, or within 6 months of a rituximab containing regimen.

9 Sep 2010

FDA grants IRIS clearance for analysis of synovial fluid with iQ200, iRICELL automated microscopy analyzers

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostic systems and consumables for use in hospitals and commercial laboratories worldwide and provider of high value personalized diagnostics testing services through its CLIA certified molecular diagnostics laboratory, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the analysis of synovial fluid as a new product application in its Body Fluids Module utilizing its iQ®200 and iRICELL® automated microscopy analyzers.

7 Sep 2010

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

A series of studies published in the September Journal of Nuclear Medicine (JNM) show that molecular imaging plays a critical role in the evaluation and treatment planning for a broad spectrum of cancers, including thyroid cancer and lymphoma.

3 Sep 2010

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Santhera Pharmaceuticals and Ipsen today announced a license agreement for the development and commercialization of fipamezole (antagonist of the adrenergic alpha-2 receptor) for territories outside of North America and Japan. This first-in-class compound is currently under investigation for the treatment of levodopa-induced dyskinesia in Parkinson's Disease.

3 Sep 2010

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, announced today the final data set from its Phase 3 study of Ketotransdel® (TDLP-110) at the 13th World Congress on Pain in Montreal, Canada.

2 Sep 2010

Sigma-Aldrich Corporation announces global release of engineered mammalian cell lines

Sigma Life Science, the innovative biological products and research services business of Sigma-Aldrich Corporation, today announced the global release of a pioneering range of engineered mammalian cell lines.

2 Sep 2010

NewYork-Presbyterian /Columbia sets up new Myelodysplastic Syndromes Center

NewYork-Presbyterian Hospital/Columbia University Medical Center has established a new center devoted to research and treatment of pre-leukemia blood disorders. Known as the Myelodysplastic Syndromes Center, it is one of the largest programs of its kind in the nation.

31 Aug 2010

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Johnson & Johnson Pharmaceutical Research & Development, announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein thrombosis (DVT), with a comparable safety profile.

31 Aug 2010

Ipsen 2010 first half revenue increases to €31.7 million

The Board of Directors of Ipsen, chaired by Jean-Luc Bélingard, met on August 30, 2010 to review the Group's results for the first half 2010, published today

31 Aug 2010

Nihon-Kohden granted exclusive rights to distribute Z-Medica's QuikClot line of hemostatic agents in Japan

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has signed an exclusive distribution agreement with Nihon-Kohden, Japan's leading manufacturer, developer and distributor of medical electronic equipment . The agreement allows Nihon-Kohden the exclusive right to distribute Z-Medica's QuikClot line of hemostatic agents to hospital, military and law enforcement markets throughout Japan. The companies have been working together since early 2009 to obtain regulatory approval.

From Medica Corporation 30 Aug 2010

Hematology News and Research

Further Reading

Pharmacyclics reports $9.3 million increase in total revenue for 2010 fiscal year

Provectus's PV-10 Phase 2 data to be presented at 7th International Melanoma Research Congress

Incyte Corporation enters SPA agreement with FDA for INCB18424 inhibitor

ARIAD commences ponatinib Phase 2 clinical trial in Ph+ ALL and chronic myeloid leukemia

LabCorp acquires Genzyme Genetics for $925 million

Cyclacel reaches SPA agreement with FDA for sapacitabine Phase 3 trial in AML

LabCorp signs five-year agreement with Sysmex America to provide hematology systems

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Researchers find risk prediction model for VTE in cancer patients

IMF and CHPF join to promote awareness of myeloma in China

GSK, Genmab commence ofatumumab Phase III study in rituximab refractory patients with indolent B-NHL

FDA grants IRIS clearance for analysis of synovial fluid with iQ200, iRICELL automated microscopy analyzers

Study shows molecular imaging benefits treatment planning for wide spectrum of cancers

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Transdel Pharmaceuticals presents Ketotransdel Phase 3 data at 13th World Pain Congress

Sigma-Aldrich Corporation announces global release of engineered mammalian cell lines

NewYork-Presbyterian /Columbia sets up new Myelodysplastic Syndromes Center

Phase 3 EINSTEIN-DVT clinical trial data can transform deep vein thrombosis treatment

Ipsen 2010 first half revenue increases to €31.7 million

Nihon-Kohden granted exclusive rights to distribute Z-Medica's QuikClot line of hemostatic agents in Japan

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News